

Infusion Site Enrollment Form

Please submit this form to:
Biogen
www.touchprogram.com
Fax: 1-800-840-1278

The TOUCH[®] Prescribing Program was developed as part of the Biogen commitment to patient safety. Only authorized infusion sites may receive shipments of and infuse TYSABRI[®] (natalizumab). An infusion site may become authorized only after it has taken part in compulsory training conducted by Biogen and designated an authorized representative to carry out the certification process and to oversee implementation and compliance with the REMS Program on behalf of the infusion site and faxed a completed Enrollment Form to Biogen. Upon receipt of this Enrollment Form, Biogen will send an authorization confirmation letter to provide your Site Authorization Number and confirm your Shipping Address.

Infusion Site Address

Name of Infusion Site			Contact name		
Address 1			Telephone		
Address 2			Fax		
City	State	ZIP	☐ Yes ☐ No The infusion site will offer services to provide in-home infusions.		

Method of acquiring TYSABRI

- 1** Infusion site will acquire TYSABRI directly. If YES, check all that apply: ☐ Buy/Bill ☐ Assignment of Benefits/Specialty Pharmacy
- OR**
- 2** Infusion site will acquire through a certified pharmacy.* ☐

*A certified pharmacy is located within a hospital, group practice, or infusion site and is associated with an infusion site. Retail pharmacies and wholesalers are excluded from holding inventory and dispensing TYSABRI.

Shipping Address

☐ Check here if address is same as above.

Name of Infusion Site or Certified Pharmacy			Contact name		
Address 1			Telephone		
Address 2			Fax		
City	State	ZIP			

I must contact Biogen if my infusion site name, administration address, or shipping address changes. By signing below, I understand that I am the TOUCH Trained Authorized Representative at the infusion site and am responsible for what is outlined in the "Infusion Site Acknowledgment" below.

Infusion Site Acknowledgment

- The infusion site has received training and educational materials on the TOUCH Prescribing Program
- TYSABRI will be administered only to patients who are currently authorized in the TOUCH Prescribing Program.
Patient authorization must be confirmed *prior to each infusion* by:
 - For TOUCH On-Line infusion sites: Patient status must be "Authorized" or
 - For paper-based infusion sites: Receipt of current Notice of Patient Authorization and verification that no Notice of Patient Discontinuation is on file
- Each patient must receive a copy of the TYSABRI Patient Medication Guide *prior to each infusion*
- The TYSABRI Pre-infusion Patient Checklist must be completed *prior to each infusion*. The Pre-infusion Patient Checklist must be submitted to Biogen within 1 business day of the patient visit regardless of whether or not the patient received the infusion by:
 - For paper-based infusion sites: sending a copy of the completed Pre-infusion Patient Checklist to Biogen. A copy must also be placed in the patient's medical record
 - For TOUCH On-Line infusion sites: the infusion nurse can read, complete and submit the Pre-Infusion Patient Checklist directly in TOUCH On-Line
- Maintain records of the infusion site's Site Authorization Confirmation
- I understand that, per the requirements of the TOUCH Prescribing Program, this infusion site's compliance may be reviewed by and/or audited by Biogen and/or a third party designated by Biogen
- I understand that infusion site contact information may be shared with the REMS programs for other natalizumab products if a patient switches to another natalizumab product
- I understand that noncompliance with the requirements of the TOUCH Prescribing Program will result in de-enrollment of the infusion site and termination of the authorization to infuse TYSABRI

Authorized Representative acknowledgment: _____ Date: _____

Name: _____ Title: _____

Please see the Prescribing Information, including **BOXED WARNING**, for more information.